Potential utility of early metabolic response by 18F-2-fluoro-2- deoxy-d-glucose-positron emission tomography/computed tomography in a selected group of breast cancer patients receiving preoperative chemotherapy

European Journal of Cancer

Volumn 49, Issue 7, 2013, Pages 1539-1545

  Zucchini, G ^a   Quercia, S ^a   Zamagni, C ^a   Santini, D ^a   Taffurelli, M ^a   Fanti, S ^a   Martoni, A A ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

18F 2 fluoro 2 deoxy d glucose positron emission tomography computed tomography; Breast cancer; Early response evaluation; Optimal pathologic response; Preoperative chemotherapy

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUORODEOXYGLUCOSE F 18; TRASTUZUMAB;

ADULT; ADVANCED CANCER; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURGERY; CLINICAL ARTICLE; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE FREE SURVIVAL; EARLY CANCER; FEMALE; FOLLOW UP; HUMAN; METABOLISM; MULTIPLE CYCLE TREATMENT; PREDICTIVE VALUE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RADIOLOGICAL PARAMETERS; SENSITIVITY AND SPECIFICITY; STANDARDISED UPTAKE VALUE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PREOPERATIVE PERIOD; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; REMISSION INDUCTION; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84876135807     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.12.024     Document Type: Article

References (40)

1. B. Fisher, A. Brown, and E. Mamounas Effect of preoperative chemotherapy on loco-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18 J Clin Oncol 15 1997 2483 2493 (Pubitemid 27289876)
2. B. Fisher, J. Bryant, and N. Wolmark Effect of preoperative chemotherapy on the outcome of women with operable breast cancer J Clin Oncol 16 1998 2672 2685 (Pubitemid 28363030)
3. I.C. Smith, S.D. Heys, and A.W. Hutcheon Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel J Clin Oncol 20 2002 1456 1466 (Pubitemid 34260523)
4. J.Y. Pierga, E. Mouret, and V. Dieras Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer Br J Cancer 83 2000 1480 1487
5. R. Rouzier, J.M. Extra, and J. Klijanienko Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes J Clin Oncol 20 2002 1304 1310 (Pubitemid 34177437)
6. C. Liedtke, C. Mazouni, and K.R. Hess Response to neoadjuvant therapy and long term survival in patients with triple negative breast cancer J Clin Oncol 26 2008 1274 1281
7. E. Montagna, V. Bagnardi, and N. Rotmensz Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline features Breast Cancer Res Treat 124 2010 689 699
8. L.A. Carey, R. Metzeger, and E.C. Dees American Joint Committee on Cancer tumor-node metastasis-stage after neoadjuvant chemotherapy and breast cancer outcome J Natl Cancer Inst 97 2005 1137 1142 (Pubitemid 41511213)
9. X. Kong, M.S. Moran, and N. Zhang Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients Eur J Cancer 47 2011 2084 2090
10. M. Colleoni, G. Viale, and D. Zahrieh Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment Clin Cancer Res 10 2004 6622 6628 (Pubitemid 39346559)
11. I.F. Fanyete, J.G. Schrama, and J.L. Peterse Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome Br J Cancer 88 2003 406 412 (Pubitemid 36308152)
12. A. Goldhirsch, W.C. Wood, and A.S. Coates Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 Ann Oncol 22 8 2001 1737 1747
13. V. Guarneri, K. Broglio, and S.W. Kau Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors J Clin Oncol 24 2006 1037 1044 (Pubitemid 46638799)
14. A.E. Ring, I.E. Smith, and S. Ashley Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer Br J Cancer 91 2004 2012 2017 (Pubitemid 40128767)
15. J. Chang, T.J. Powles, and D.C. Alfred Biologic markers as predictors of clinical outcome for systemic therapy for primary operable breast cancer J Clin Oncol 17 1999 3058 3063 (Pubitemid 29470633)
16. P. Ellis, I. Smith, and S. Ashley Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer J Clin Oncol 16 1998 107 114 (Pubitemid 28041586)
17. G. von Minckwitz, S. Kümmel, and P. Vogel Intensified neoadjuvant chemotherapy in early responding breast cancer: phase III randomized GeparTrio study J Natl Cancer Inst 100 2008 552 562
18. G. von Minckwitz, S. Kümmel, and P. Vogel Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide kin early nonresponsive breast cancer: phase III randomized GeparTrio trial J Natl Cancer Inst 100 2008 542 551
19. A.F. Schott, M.A. Roubidoux, and M.A. Helvie Clinical and radiologic assessments to predict breast cancer pathologic complete response to neoadjuvant chemotherapy Breast Cancer Res Treat 92 2005 231 238 (Pubitemid 41282819)
20. 18F]-fluorodeoxy-d-glucose to predict the pathologic response of breast cancer to primary chemotherapy J Clin Oncol 18 2000 1676 1688 (Pubitemid 30220546)
21. 18F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer J Clin Oncol 18 2000 1689 1695 (Pubitemid 30220547)
22. 18F]fluorodeoxyglucose positron emission tomography J Clin Oncol 24 2006 5366 5372 (Pubitemid 46623167)
23. 18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy Eur J Nucl Med Mol Imaging 34 2007 1915 1924 (Pubitemid 350212117)
24. 18F]fluorodeoxyglucose J Clin Oncol 27 2008 535 541
25. A. Kumar, R. Kumar, and V. Seenu The role of (18)F-FDG PET/CT in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced breast cancer Eur Radiol 19 2009 1347 1357
26. J. Duch, D. Fuster, and M. Munoz (18)F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer Eur J Nucl Med Mol Imaging 36 2009 1551 1557
27. 18F-2-fluoro-2- deoxy-d-glucose positron emission tomography may identify a subset of patients with estrogen receptor-positive breast cancer who will not respond optimally to preoperative chemotherapy Cancer 116 2010 805 813
28. D. Mauri, N. Pavlidis, and J.P. Ioannidis Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis J Natl Cancer Inst 97 2005 188 194 (Pubitemid 40277368)
29. J.H. Chen, B. Feig, and G. Agrawal MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy Cancer 112 2008 17 26
30. S.J. Vinnicombe, A.D. MacVicar, and R.L. Guy Primary breast cancer: mammographic changes after neoadjuvant chemotherapy, with pathologic correlation Radiology 198 1996 333 340 (Pubitemid 26036832)
31. S. Ngamruengphong, V.K. Sharma, and B. Nguyen Assessment of response to neoadjuvant therapy in esophageal cancer: an updated systematic review of diagnostic accuracy of endoscopic ultrasonography and fluorodeoxyglucose positron emission tomography Dis Esophagus 23 2010 216 231
32. L. Kostakoglu Goldsmith SJ (2004) PET in the Assessment of Therapy Response in Patients with Carcinoma of the Head and Neck and of the Esophagus J Nucl Med 45 2004 56 68 (Pubitemid 47611611)
33. V. Kalff, C. Duong, and E.G. Drummond Findings of 18F-FDG PET scans after neoadjuvant chemoradiation provides prognostic stratification in patients with locally advanced rectal carcinoma subsequently treated by radical surgery J Nucl Med 47 2006 14 22 (Pubitemid 46768507)
34. Y. Yamamoto, Y. Nishiyama, and T. Monden Correlation of FDG PET findings with histopathology in the assessment of response to induction chemoradiotherapy in non-small cell lung cancer Eur J Nucl Med Mol Imaging 33 2006 140 147 (Pubitemid 43152880)
35. H. Kolesnikov-Gauthier, L. Vanlemmens, and M.C. Baranzelli Predictive value of neoadjuvant chemotherapy failure in breast cancer using FDG-PET after the first course Breast Cancer Res Treat 131 2012 517 525
36. B. Keam, S.A. Im, and Y. Koh Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy BMC Cancer 11 2011 452
37. 18F-FDG PET/CT: defining a clinical aim Eur J Nucl Med Mol Imaging 38 2011 419 425
38. Y. Wang, C. Zhang, and J. Liu Is 18F-FDG PET accurate to predict neoadjuvant therapy response in breast cancer? A meta-analysis Breast Cancer Res Treat 131 2 2012 357 369
39. K.N. Ogston, I.D. Miller, and S. Payne A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival Breast 12 2003 320 327 (Pubitemid 37322062)
40. L.H. Sobin, and C. Wittekind International Union Against Cancer (UICC). TNM classification of malignant tumors 6th ed. 2002 John Wiley & Sons New York